Damora Therapeutics (DMRA) Non Operating Investment Income (2021 - 2024)
Damora Therapeutics (DMRA) reported Non Operating Investment Income of $2000.0 for Q2 2024, down 92.0% on a YoY basis from $25000.0 in Q3 2023, and down 93.75% quarter-over-quarter from $32000.0 in Q1 2024.
Damora Therapeutics (DMRA) Non Operating Investment Income (2021 - 2024) Analysis & Trends
Damora Therapeutics has reported Non Operating Investment Income for 4 years, with the latest figure at $2000.0 in Q2 2024.
- For the quarter ending Q2 2024, Non Operating Investment Income fell 92.0% year-over-year to $2000.0; the trailing twelve-month figure through Sep 2024 stood at $92000.0 (down 74.16% YoY), and the FY2023 full-year result was $231000.0, up 189.19% from the prior year.
- Non Operating Investment Income for Q2 2024 stood at $2000.0, down from $32000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $183000.0 in Q4 2022, with the low at -$205000.0 in Q1 2022.
- Historically, Non Operating Investment Income has averaged -$5071.4 across 4 years, with a median of $24000.0 in 2021.
- The largest YoY upside for Non Operating Investment Income was 438.89% in 2022 against a maximum downside of 773.91% in 2022.
- Damora Therapeutics' Non Operating Investment Income stood at -$54000.0 in 2021, then soared by 438.89% to $183000.0 in 2022, then plunged by 68.31% to $58000.0 in 2023, then slumped by 96.55% to $2000.0 in 2024.
- The last three Non Operating Investment Income figures came in at $2000.0 (Q2 2024), $32000.0 (Q1 2024), and $58000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Sep 30, 2023 | 56,000.00 |
| Sep 30, 2023 | 56,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Mar 31, 2023 | 92,000.00 |
| Mar 31, 2023 | 92,000.00 |
| Dec 31, 2022 | 183,000.00 |
| Dec 31, 2022 | 183,000.00 |
| Sep 30, 2022 | -82,000.00 |
| Sep 30, 2022 | -82,000.00 |
| Jun 30, 2022 | -155,000.00 |
| Jun 30, 2022 | -155,000.00 |
| Mar 31, 2022 | -205,000.00 |
| Mar 31, 2022 | -205,000.00 |